FMP

FMP

Enter

BYSI - BeyondSpring Inc.

Financial Summary of BeyondSpring Inc.(BYSI), BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focus

photo-url-https://financialmodelingprep.com/image-stock/BYSI.png

BeyondSpring Inc.

BYSI

NASDAQ

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

2.09 USD

0.03 (1.44%)

About

ceo

Dr. Lan Huang Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.beyondspringpharma.com

exchange

NASDAQ

Description

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the tre...

CIK

0001677940

ISIN

KYG108301006

CUSIP

G10830100

Address

28 Liberty Street

Phone

646 305 6387

Country

US

Employee

73

IPO Date

Mar 9, 2017

Summary

CIK

0001677940

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

G10830100

ISIN

KYG108301006

Country

US

Price

2.09

Beta

0.17

Volume Avg.

226.5k

Market Cap

81.54M

Shares

-

52-Week

0.653-4.0

DCF

-0.5

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-2.94

P/B

-

Website

https://www.beyondspringpharma.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest BYSI News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep